[{"address1": "321 Harrison Avenue", "address2": "11th Floor, Suite 1", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 453 3596", "website": "https://www.pyxisoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 44, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lara S. Sullivan M.D., MBA", "title": "CEO, President, Chief Medical Officer & Director", "fiscalYear": 2024, "totalPay": 1057225, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Pamela Yanchik Connealy M.B.A.", "age": 62, "title": "CFO & COO", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 763830, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Balu N. Balasubramanian Ph.D.", "title": "Interim Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jan  Pinkas Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Charles T. Gombar Ph.D.", "title": "Senior Vice President of Portfolio & Program Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen T. Worsley MBA", "age": 60, "title": "Senior VP & Chief Business Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Bui", "title": "Head of Global Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Supriya  Roth Ph.D.", "title": "Head of Commercial Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shui  He Ph.D.", "title": "Head of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hongwei  Wang M.D., Ph.D.", "title": "Head of ADC Development & Clinical Strategy", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.07, "open": 1.075, "dayLow": 1.06, "dayHigh": 1.17, "regularMarketPreviousClose": 1.07, "regularMarketOpen": 1.075, "regularMarketDayLow": 1.06, "regularMarketDayHigh": 1.17, "payoutRatio": 0.0, "beta": 1.148, "forwardPE": -0.9285714, "volume": 278659, "regularMarketVolume": 278659, "averageVolume": 592368, "averageVolume10days": 454700, "averageDailyVolume10Day": 454700, "bid": 1.06, "ask": 1.15, "bidSize": 1, "askSize": 1, "marketCap": 68452208, "fiftyTwoWeekLow": 0.833, "fiftyTwoWeekHigh": 5.39, "priceToSalesTrailing12Months": 4.239577, "fiftyDayAverage": 1.0627, "twoHundredDayAverage": 2.357625, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -40829256, "profitMargins": 0.0, "floatShares": 44339556, "sharesOutstanding": 61947700, "sharesShort": 7131225, "sharesShortPriorMonth": 6924016, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.1158, "heldPercentInsiders": 0.22456, "heldPercentInstitutions": 0.39372003, "shortRatio": 14.99, "shortPercentOfFloat": 0.1396, "impliedSharesOutstanding": 61947700, "bookValue": 2.014, "priceToBook": 0.5486594, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -77331000, "trailingEps": -1.32, "forwardEps": -1.19, "enterpriseToRevenue": -2.529, "enterpriseToEbitda": 0.652, "52WeekChange": -0.76274943, "SandP52WeekChange": 0.08001411, "quoteType": "EQUITY", "currentPrice": 1.105, "targetHighPrice": 8.0, "targetLowPrice": 5.0, "targetMeanPrice": 6.0, "targetMedianPrice": 5.5, "recommendationMean": 1.66667, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 126931000, "totalCashPerShare": 2.061, "ebitda": -62588000, "totalDebt": 20200000, "quickRatio": 7.179, "currentRatio": 7.491, "totalRevenue": 16146000, "debtToEquity": 16.729, "revenuePerShare": 0.276, "returnOnAssets": -0.24768999, "returnOnEquity": -0.62755, "grossProfits": 15671000, "freeCashflow": -33791248, "operatingCashflow": -57672000, "grossMargins": 0.97058, "ebitdaMargins": 0.0, "operatingMargins": -4.06107, "financialCurrency": "USD", "symbol": "PYXS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Pyxis Oncology, Inc.", "corporateActions": [], "regularMarketTime": 1746723830, "exchange": "NMS", "messageBoardId": "finmb_629268721", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 3.2710247, "regularMarketPrice": 1.105, "hasPrePostMarketData": true, "shortName": "Pyxis Oncology, Inc.", "marketState": "REGULAR", "firstTradeDateMilliseconds": 1633699800000, "regularMarketChange": 0.034999967, "regularMarketDayRange": "1.06 - 1.17", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 592368, "fiftyTwoWeekLowChange": 0.272, "fiftyTwoWeekLowChangePercent": 0.32653064, "fiftyTwoWeekRange": "0.833 - 5.39", "fiftyTwoWeekHighChange": -4.285, "fiftyTwoWeekHighChangePercent": -0.7949907, "fiftyTwoWeekChangePercent": -76.27494, "earningsTimestamp": 1742297400, "earningsTimestampStart": 1747053000, "earningsTimestampEnd": 1747398600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.32, "epsForward": -1.19, "epsCurrentYear": -1.276, "priceEpsCurrentYear": -0.8659875, "fiftyDayAverageChange": 0.042299986, "fiftyDayAverageChangePercent": 0.039804257, "twoHundredDayAverageChange": -1.252625, "twoHundredDayAverageChangePercent": -0.531308, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2021-10-08", "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "displayName": "Pyxis Oncology", "trailingPegRatio": null, "__fetch_time": "2025-05-08"}]